Case reportPublished 13 Oct 2017
Apresoline Promoted Acrolein Reduction in Patient with Relapsing Remitting Multiple Sclerosis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Acrolein has been implicated as an irritating/exacerbating factor in animal models of relapsingremitting multiple sclerosis. In animal studies, Apresoline (Hydralazine) has acted as a successful acrolein scavenging agent and resulted in reduced behavioral deficits and decreased myelin damage. It has been hypothesized that Apresoline would be equally successful as a disease modifying treatment for relapsing-remitting multiple sclerosis. Objective: To describe the case of acrolein reduction in a patient with relapsing-remitting multiple sclerosis taking Apresoline. Methods: Case study. Results: The patient was diagnosed with relapsing-remitting multiple sclerosis and found to have an elevated level of acrolein. After 60 days of Apresoline treatment, the patient’s acrolein level was reduced to a normal level. Dosage was reduced to establish a minimum effective dosage with no assessed increase in relapsing-remitting multiple sclerosis activity. Conclusion: Elevated levels of acrolein were documented in this relapsing-remitting multiple sclerosis patient. Apresoline was demonstrated to be an effective acrolein scavenger in this patient and a minimum effective dosage was established.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “David Alan Olges”
- BylineArticles whose byline prints “Vanessa Wyche Graham”